Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer (ABCSG C08)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03822572
Recruitment Status : Recruiting
First Posted : January 30, 2019
Last Update Posted : October 14, 2020
Sponsor:
Collaborator:
Oberösterreichische Krebshilfe
Information provided by (Responsible Party):
Austrian Breast & Colorectal Cancer Study Group

Brief Summary:

ABCSG C08 is a randomized, two-arm, multicenter trial to investigate the efficacy of endurance exercise following adjuvant chemotherapy in patients with colorectal cancer.

Indication: Locally advanced colorectal cancer after adjuvant chemotherapy. Evidence supporting the beneficial effects of exercise programs during chemotherapy are available, the results across studies are not entirely consistent. Additional studies are needed to determine the optimal content, intensity, and form of training programs.


Condition or disease Intervention/treatment Phase
Colorectal Carcinoma Other: endurance exercise Other: control Not Applicable

Detailed Description:

Colorectal cancer is the second leading cause of cancer mortality in Western countries after breast cancer among women and lung cancer among men. About 5.000 new cases are diagnosed each year in Austria. This represents an annual incidence of 50-60 per 100.000 inhabitants. In patients with colorectal cancer stage III and in certain situations even in stage II adjuvant chemotherapy is indicated after R0 resection. Despite recent advances in adjuvant chemotherapy 20-30% of these patients still relapse. About 80% of recurrences occur in the first three years.

There is consistent evidence from several observational epidemiologic studies that physical activity reduces the risk of developing colon cancer. In recent years several observational studies even showed a reduction in relapse rate, colon cancer-specific mortality and overall mortality by physical activity in patients with colon and breast cancer. Colon cancer survivors who engaged in higher levels of physical activity experienced a 50-60% improvement in long-term outcomes compared to inactive patients. Different mechanisms for the protective effect of physical activity on colon cancer have been proposed and it is believed that the same mechanisms of physical activity are also involved in the improvement of disease outcomes in gastrointestinal cancer survivors. Physical activity leads to decrease of inflammation, decreased levels of insulin-like growth factor (IGF) and insulin, reduced transit time through the gut and increased levels of vitamin D. Factors, that are associated with a reduced risk of colon polyps, colon cancer and colon cancer mortality.

A review on the impact of various exercise programs on fatigue, found good evidence that exercise not only decreased levels of fatigue, but also increased quality of life, mood and functioning.

While there is evidence supporting the beneficial effects of exercise programs during chemotherapy, the results across studies are not entirely consistent. Additional studies are needed to determine the optimal content, intensity, and form of training programs.

Recently ABCSG has investigated the feasibility of endurance exercise after adjuvant chemotherapy in patients with locally advanced colorectal cancer in the investigator's study group (ABCSG C07 Exercise - pilot study). Results concerning compliance of patients have been considered for sample size estimations and study planning.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 788 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: ABCSG C08 - Exercise II: Randomized Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer
Actual Study Start Date : February 14, 2019
Estimated Primary Completion Date : December 2026
Estimated Study Completion Date : December 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: A - endurance exercise
All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
Other: endurance exercise
defined exercise program

B - control arm
Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
Other: control
habitual physical activity before the diagnosis




Primary Outcome Measures :
  1. Primary Endpoint - disease free survival (DFS) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    DFS is defined as the time from randomization to locoregional or metastatic recurrence or the appearance of secondary cancer or death, whichever occurs first. Recurrence may be either histologically proven or evidenced by imaging via MRI or CT. Isolated CEA evaluation will not be sufficient to determine a relapse.


Secondary Outcome Measures :
  1. Secondary Efficacy Endpoint I - relapse free survival (RFS) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    RFS is defined as the time from randomization to locoregional or metastatic recurrence of colorectal cancer or death, whichever occurs first

  2. Secondary Efficacy Endpoint II - overall survival (OS) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    OS is defined as time from randomization to death from any cause

  3. Physical Activity Endpoint I - physical activity measured by MET-hours [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of physical activities measured by MET-hours in the domains "work", "leisure time ", "sedentary behavior" and "transporation" by Global Physical Activity Questionnaire (GPAQ) within each study arm and compared between study arms at baseline, at 3, at 6, at 12, at 24 and at 36 months

  4. Physical Activity Endpoint II - endurance exercise measured by MET-hours [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of endurance exercise measured by MET-hours by pulse-control in arm A at 3, at 6 and at 12 months

  5. Physical Activity Endpoint III - performance enhancement measured by MET-hours by ergometry [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of performance enhancement measured by MET-hours by ergometry within each study arm (arm A at baseline, at 3, at 6 and at 12 months; arm B at baseline and at 12 months) and compared between study arms at baseline and at 12 months

  6. Physical Activity Endpoint IV - physical activity measures [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Correlation of MET-hours in the domains "work", "leisure time ", "sedentary behavior" and "transporation" by Global Physical Activity Questionnaire (GPAQ) and results of endurance exercise as well as performance enhancement by ergometry (both measured by MET-hours) with DFS, RFS and OS

  7. Patient Reported Outcome Endpoint I - fatigue [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of fatigue as measured by EORTC - QLQ FATIGUE CAT Theta scores compared between study arms. Score has no fixed upper and lower limit and a high score represents a high level of fatigue.

  8. Patient Reported Outcome Endpoint II - emotional functioning score [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the emotional functioning score (based in the functional scale EF) as measured by EORTC QLQ-C30 emotional functioning (based on items) compared between study arms, where a high score for a functional scale represents a high/healthy level of functioning.

  9. Patient Reported Outcome Endpoint III - physical functioning score [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the standardized physical functioning score (based on the revised functional scale PF2) as measured by EORTC QLQ-C30 physical functioning compared between study arms, where a high score for a functional scale represents a high/healthy level of functioning

  10. Patient Reported Outcome Endpoint IV - global quality of life (QoL) score [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the standardized global health status/QoL score (based on the revised global health status/QoL QL2) as measured by EORTC QLQ-C30 summary score compared between study arms, where a high score for the global health status/QoL represents a high QoL.

  11. Patient Reported Outcome Endpoint V - patient reported outcomes (fatigue, emotional functioning, physical functioning, global quality of life) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Correlation of all patient reported outcomes explained above (fatigue, emotional functioning, physical functioning, global quality of life) with MET-hours

  12. Body Composition Endpoint I - body mass index (BMI) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the influence of BMI on DFS, RFS and OS

  13. Body Composition Endpoint II - body fat [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the influence of body fat on DFS, RFS and OS

  14. Body Composition Endpoint III - waist circumference [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the influence of waist circumference on DFS, RFS and OS

  15. Cardiovascular Endpoint - cardiovascular complications [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the incidence of cardiovascular complications (myocardial infarction, stroke, newly diagnosed diabetes mellitus, newly diagnosed hypertension)

  16. Safety Endpoint I - serious adverse events (SAEs) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of the incidence of physical activity related SAEs and physical activity related deaths in both arms

  17. Safety Endpoint II - time to SAEs [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Evaluation of time from study start to physical activity related SAEs

  18. Exploratory Endpoint - molecular and biochemical markers (will be defined during the course of the study) [ Time Frame: 8 years (after Last Patient Out (LPO)) ]
    Correlation of molecular and biochemical markers with DFS, RFS, OS and with physical activity. The analysis of molecular markers will depend on the markers which will be defined during the course of the study in addition to Insulin & ILGF.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • completely resected, histologically confirmed adenocarcinoma of the colon or rectum
  • patients, who have completed adjuvant chemotherapy 4-16 weeks prior to randomization
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Age ≥18 years
  • adequate hematologic functions <=28d prior to randomization
  • able to perform endurance exercise according to protocol
  • ability to perform ergometry in order to assess physical capability at the discretion of the investigator
  • signed informed consent prior to randomization

Exclusion Criteria:

  • significant comorbid conditions precluding participation in a physical activity program (investigators decision)
  • disabled patients unable to participate in the physical activity program
  • Regular (3-times a week) vigorous physical activity of >150 minutes (type of physical activity: bicycling, cross walking (cross trainer), jogging, walking at a brisk pace, nordic walking, cross country skiing) within the last year before diagnosis of colorectal cancer
  • patients unwilling to complete endurance exercise or complete all questionnaires related to the study
  • past or current history of other malignant neoplasms other than colorectal cancer in the last 5 years except basal cell carcinoma of the skin and/or in situ carcinoma of the cervix
  • clinically significant cardiovascular disease
  • left bundle branch block
  • current study with chemotherapy or radiation
  • current pregnancy or plans to become pregnant within the next 3 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03822572


Contacts
Layout table for location contacts
Contact: Martina Putz, PhD +43 1 4089230 martina.putz@abcsg.at
Contact: Aleksandra Mystek, BBSc +43 1 4089230 aleksandra.mystek@abcsg.at

Locations
Layout table for location information
Austria
Med. Univ. Graz Not yet recruiting
Graz, Styria, Austria, 8036
Contact: Thomas Bauernhofer, MD         
Principal Investigator: Thomas Bauernhofer, MD         
BKH Kufstein Recruiting
Kufstein, Tyrol, Austria, 6330
Contact: August Zabernigg, MD, Head         
Principal Investigator: August Zabernigg, MD, Head         
KH St. Josef Braunau Recruiting
Braunau Am Inn, Upper Austria, Austria, 5280
Contact: Sigrid Kastner, MD, Head         
Principal Investigator: Sigrid Kastl, MD, Head         
Hospital BHS Linz, Coop. Study Group Recruiting
Linz, Upper Austria, Austria, 4010
Contact: Andreas Petzer, MD, Head         
Principal Investigator: Andreas Petzer, MD         
Kepler Universitätsklinikum Linz Not yet recruiting
Linz, Upper Austria, Austria, 4020
Contact: Gerhard Hochreiner, MD         
Principal Investigator: Hochreiner, MD         
Hospital BHS Ried Not yet recruiting
Ried, Upper Austria, Austria, 4910
Contact: Alexander Andorfer, MD         
Principal Investigator: Alexander Andorfer, MD         
State Hospital Steyr Not yet recruiting
Steyr, Upper Austria, Austria, 4400
Contact: Johannes Andel, MD, Head         
Principal Investigator: Johannes Andel, MD, Head         
Klinikum Wels-Grieskirchen Recruiting
Wels, Upper Austria, Austria, 4600
Contact: Josef Thaler, MD, Head         
Principal Investigator: Josef Thaler, MD         
LKH Salzburg-PMU, UNiv. KLinik f. Innere Med III Not yet recruiting
Salzburg, Austria, 5020
Contact: Richard Greil, MD, Head         
Principal Investigator: Richard Greil, MD, Head         
Sponsors and Collaborators
Austrian Breast & Colorectal Cancer Study Group
Oberösterreichische Krebshilfe
Investigators
Layout table for investigator information
Study Chair: Josef Thaler, MD Austrian Breast & Colorectal Cancer Study Group
Layout table for additonal information
Responsible Party: Austrian Breast & Colorectal Cancer Study Group
ClinicalTrials.gov Identifier: NCT03822572    
Other Study ID Numbers: ABCSG C08
First Posted: January 30, 2019    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: currently sharing of IPDs (Individual Participant Data) is not planned in this trial

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Austrian Breast & Colorectal Cancer Study Group:
endurance exercise
Additional relevant MeSH terms:
Layout table for MeSH terms
Rectal Diseases
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases